Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells

Cancer Gene Therapy volume 14, pages 431–439 (2007)Cite this article

Abstract

In this report, the effects of a combined treatment with the proteasome inhibitor bortezomib and either a recombinant adeno-associated virus type 2 (rAAV-2)-mediated p53 gene transfer or chemotherapeutic agents, docetaxel and pemetrexed, were tested on p53 positive and p53negative non-small cell lung cancer (NSCLC) cell lines. The combination of bortezomib and rAAV-p53 led to a significant synergistic inhibition of cell growth between 62–82% depending on the p53 status of the cell line and drug concentration. Surviving cells of the combined treatment showed a significant reduced ability to form colonies. Enhanced cell toxicity was associated with a 5.3–14.4-fold increase of the apoptotic rate and intracellular p53 level up to 50.4% following vector-mediated p53 restoration and bortezomib treatment. In contrast, an antagonistic effect on tumor cell growth and colony formation was observed for the combination of bortezomib and docetaxel or pemetrexed as a reduction of cell growth between 31 and 48% was found in comparison to 50% using the single agents. Lower cytotoxic effects were associated with significantly reduced apoptosis and an increase of clonogenic growth. The observed antagonistic effects between bortezomib and docetaxel or pemetrexed might influence clinical trials using these compounds. Conversely, p53 restoration and bortezomib treatment led to enhanced, synergistic tumor cell toxicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 45: 8–29.

    Article  Google Scholar 

  2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92–98.

    Article  CAS  Google Scholar 

  3. Engels FK, Sparreboom A, Mathot RAA, Verweij J . Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005; 93: 173–177.

    Article  CAS  Google Scholar 

  4. Adjei AA . Pemetrexed (Alimta), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004; 10: 4276–4280.

    Article  Google Scholar 

  5. Hanna N, Sheperd F, Rosell R, Pereira JR, De Marinis F, Fossella F et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer previously treated with chemotherapy. Am Soc Clin Oncol 2003; 22: 622.

    Google Scholar 

  6. Roth JA, Grammer SF . Gene replacement therapy for non-small cell lung cancer: a review. Hematol Oncol Clin N Am 2004; 18: 215–229.

    Article  Google Scholar 

  7. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Nat Cancer Inst 1999; 91: 763–771.

    Article  CAS  Google Scholar 

  8. Maione P, Rossi A, Airoma G, Ferrara C, Castaldo V, Gridelli C . The role of targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol 2004; 51: 29–44.

    Article  Google Scholar 

  9. Adams J . Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9–16.

    Article  CAS  Google Scholar 

  10. Ludwig H, Khayat D, Giaccone G, Facon T . Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005; 104: 1794–1807.

    Article  CAS  Google Scholar 

  11. Scagliotti G . Proteasome inhibition in lung cancer. Crit Rev Oncol Hematol 2006; 58: 177–189.

    Article  Google Scholar 

  12. Adams J . The proteasome: structure, function and role in the cell. Cancer Treat Rew 2003; 29: 3–9.

    Article  CAS  Google Scholar 

  13. Ling Y-H, Liebes L, Jiang J-D, Holland JF, Elliott PJ, Adams J et al. Mechanisms of proteasome inhibitor PS-341-induced G2–M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9: 1145–1154.

    CAS  PubMed  Google Scholar 

  14. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ . Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54: 343–353.

    Article  CAS  Google Scholar 

  15. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H . Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004; 95: 176–180.

    Article  CAS  Google Scholar 

  16. Chen F, Chang D, Goh M, Klibanov SA, Ljungman M . Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 2000; 11: 239–246.

    CAS  PubMed  Google Scholar 

  17. Lopes UG, Erhardt P, Yao R, Cooper GM . P53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272: 12893–12896.

    Article  CAS  Google Scholar 

  18. Ren J, Shi M, Liu R, Yang Q-H, Johnson T, Skarnes WC et al. The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci 2005; 102: 565–570.

    Article  CAS  Google Scholar 

  19. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S et al. P53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 171–180.

    CAS  PubMed  Google Scholar 

  20. Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R et al. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector. Cancer Gene Ther 2003; 10: 898–906.

    Article  CAS  Google Scholar 

  21. Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R . Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods 2002; 106: 81–89.

    Article  CAS  Google Scholar 

  22. Hörster A, Teichmann B, Hormes R, Grimm D, Kleinschmidt J, Sczakiel G . Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression and show anti-HIV-1 efficacy. Gene Therapy 1999; 6: 1231–1238.

    Article  Google Scholar 

  23. Grimm D, Kern A, Rittner K, Kleinschmidt JA . Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Therapy 1998; 9: 2745–2760.

    Article  CAS  Google Scholar 

  24. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973–985.

    Article  CAS  Google Scholar 

  25. Rohr UP, Heyd F, Neukirchen J, Wulf MA, Queitsch I, Kroener-Lux G et al. Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J Virol Methods 2005; 127: 40–45.

    Article  CAS  Google Scholar 

  26. Vayssade M, Haddada H, Faridoni-Laurens L, Tourpin S, Valent A, Benard J et al. p73 functionally replaces p53 in adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005; 116: 860–869.

    Article  CAS  Google Scholar 

  27. Richardson PG, Hideshima T, Anderson KC . Bortezomib: a novel, first-in-class proteasome inhibitor for the treatment of multiple meyloma and other cancers. Cancer Control 2005; 10: 361–369.

    Article  Google Scholar 

  28. Campling BG, El-Deiry WS . Clinical implication of p53 mutation in lung cancer. Mol Biotech 2003; 24: 141–156.

    Article  CAS  Google Scholar 

  29. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and novel visualisation tools. Nucleic Acids Res 1998; 26: 205–213.

    Article  CAS  Google Scholar 

  30. Levine AJ . P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331.

    Article  CAS  Google Scholar 

  31. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M et al. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlation with the growth inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285–4300.

    CAS  PubMed  Google Scholar 

  32. Rohr UP, Kronenwett R, Grimm D, Kleinschmidt J, Haas R . Primary human cell differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. J Virol Methods 2002; 105: 265–275.

    Article  CAS  Google Scholar 

  33. Swisher SG, Roth JA, Komaki R, Hicks M, Ro J, Dreiling L et al. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Am Soc Clin Oncol 2000; 19: 461a.

    Google Scholar 

  34. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J Clin Oncol 2000; 18: 609–622.

    Article  CAS  Google Scholar 

  35. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750–1758.

    Article  CAS  Google Scholar 

  36. Nawrocki ST, Sweeny-Gotsch B, Takamori R, McConkey DJ . The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004; 3: 59–70.

    CAS  PubMed  Google Scholar 

  37. Kut V, Patel JD, Argiris A . Pemtrexed: a novel antifolate agent enters clinical practice. Expert Rev Anticancer Ther 2004; 4: 511–522.

    Article  CAS  Google Scholar 

  38. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521–531.

    Article  CAS  Google Scholar 

  39. Hennequin C, Giocanti N, Favaudon V . S-phase specificity of cell killing by docetaxel (Taxotere) in synchronized HeLa cells. Br J Cancer 1995; 71: 1194–1198.

    Article  CAS  Google Scholar 

  40. Ling Y-H, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2 Mphase arrest and apoptosis. Mol Cancer Ther 2002; 1: 841–849.

    CAS  PubMed  Google Scholar 

  41. Fanucchi MP, Fossella F, Fidias P . Bortezomib±docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 study. Am Soc Clin Oncol 2005; Abstract No: 7024.

Download references

Acknowledgements

This work was supported by the Research commission of the Medical Faculty, University Duesseldorf and the Leukaemie Liga eV. Duesseldorf.

Author information

Authors and Affiliations

  1. Klinik für Haematologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universitaet Duesseldorf, Duesseldorf, Germany

    J Neukirchen, A Meier, A Rohrbeck, G Garcia-Pardillos, R Fenk, R Haas, R Kronenwett & U-P Rohr

  2. Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston, MA, USA

    U Steidl

Authors
  1. J Neukirchen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Rohrbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Garcia-Pardillos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U Steidl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Fenk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Kronenwett
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. U-P Rohr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U-P Rohr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neukirchen, J., Meier, A., Rohrbeck, A. et al. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. Cancer Gene Ther 14, 431–439 (2007). https://doi.org/10.1038/sj.cgt.7701029

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7701029

Keywords

This article is cited by

Search

Advanced search

Quick links